Barrington Research Downgrades SurModics (SRDX) to Market Perform
More News related to SRDX
- SurModics (SRDX) Misses Q4 EPS by 4c
- SurModics Reports Fourth Quarter and Fiscal Year 2009 Results
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- SurModics and NuPathe Partner to Develop Novel Long-Acting Parkinson's Treatment
- SurModics to Webcast Fourth Quarter and Fiscal Year 2009 Earnings Conference Call November 4
Barrington Research downgrades SurModics (Nasdaq: SRDX) from Outperform to Market Perform.
To see more analyst ratings on SRDX Click Here.
SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry.
Related Categories
DowngradesStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
